
Research Group Identifies Potential Therapeutic Target for Lupus
Inhibiting IRE1α, a molecule activated by the endoplasmic reticulum in neutrophils, counters disease progression in lupus mice.
Inhibiting IRE1α, a molecule activated by the endoplasmic reticulum in neutrophils, counters disease progression in lupus mice.
Research finds juvenile myositis and lupus share an inflammatory pathway, but their pathophysiological differences may serve as diagnostic biomarkers in future studies.
A meta-analysis of lupus finds the disease is less common than previously thought, but disproportionally affects women and racial and ethnic minorities of both sexes.
Study finds NAD+ break down leads to multi organ scarring, providing now a previously undiscovered pathogenic role of the enzyme CD38 in disease scarring.
Researchers find that a protein in the skin of patients with lupus enables staph bacteria to stick to their skin.
It’s often difficult to manage patients with this skin inflammation, but new research identifies a target that existing medications are able to address.